Mammalian Cell-based Library Screening, TARGATT™ Rapid Site-specific Integration Technology

January 22, 2021

Webinar Description:

Applied StemCell's TARGATT™ site-specific transgene knockin technology provides a very efficient platform for stable cell line generation and for mammalian cell-based library screening. For this, TARGATT™ Master Cell Lines are engineered to carry an integrase recognition landing pad, "attP" in a preselected, intergenic, safe harbor locus. The TARGATT™ integrase then mediates a unidirectional recombination between the attP sites in the cell line and attB sites on the donor plasmid to integrate the gene of interest into the specific locus. - Controlled copy number insertion: one copy per cell - Low biosafety level: eliminate need for virus-based libraries - High integration efficiency (10-30%): efficiency will impact attainable library sizes - Consistent expression across constructs (defined locus) - Medium to high protein expression We have TARGATT™ Master Cell Lines available in the HEK293, CHO and iPSC cell backgrounds.


Ruby Yanru Chen-Tsai, Ph.D.
CEO and President, Applied StemCell

Dr. Chen-Tsai received her PhD from Cornell University and did her post-doc research at Stanford University. She has been doing research in genome editing and stem cells over 20 years. Prior to joining ASC, Dr. Chen-Tsai worked at Stanford University for 16 years as the Director of Transgenic Research Center and Associate Director of the Stanford Cancer Institute, overseeing nine research technology labs. Her research at Stanford focused on using Parkinson patient-specific iPS cell lines and their differentiation to dopaminergic neurons as a disease model-in-a-dish. She is a co-inventor of the TARGATT™ integrase technology for site-specific gene insertion. Dr. Chen-Tsai is an author of many scientific papers and holder of over fifteen patents. Prior to becoming the CEO of Applied StemCell, Dr. Chen-Tsai led the ASC Therapeutics' gene/cell therapeutic pipeline in the past 5 years. She also led the successful filing of three pre-IND (one stem cell therapy, one gene therapy and one gene editing therapy) with the FDA.

Cost: No Cost!